Jefferies London 2026: Generate Biomedicines' CEO Mike Nally describes the rationale behind a recent CAR-T deal with Anthropic, updates us on the company's TSLP, and more
He describes the win-win nature of working with Anthropic, which is related to redesigning CAR T-Cell Signaling. Plus, he discusses room for improvement in the TSLP space and why he believes Generate's candidate could be best in class.
Coverage brought to you by










.png)
